Abstract:
PURPOSE: A non-ionic amphiphilic reactive precursor is provided to form nanoparticles such as micelle, and to easily convert a core part into crosslinked amphiphilic nanocapsule. CONSTITUTION: A non-ionic amphiphilic reactive precursor is used for manufacturing a nanocapsule which supports an effective antibacterial material. The non-ionic amphiphilic reactive precursor has a hydrophilic segment and a hydrophobic segment and is denoted by chemical formula 1. A method for preparing the non-ionic amphiphilic reactive precursor for manufacturing the nanocapsule comprises: a step of stirring polypropylene triol and diisocyanate in a molar ratio of 1:3 under the nitrogen atmosphere; a step of adding hydroxyl acrylate or hydroxyl methacrylate in a molar ratio of 1:2; and a step of adding polyethylene oxide and stirring.
Abstract:
A composition comprising 8-(tosylamino)quinoline is provided to inhibit production of nitric oxide, growth of cancer cells and C6 glioma cell, production of PGE2(prostaglandin 2), and activity of IKK(I kappa B alpha kinase) and Src kinase, thereby preventing or treating inflammatory diseases, immune diseases or tumors. The composition for preventing or treating inflammatory diseases, immune diseases or tumors comprises 8-(tosylamino)quinoline or pharmaceutically acceptable salts thereof including an acid addition salt selected from hydrochloric acid, hydrobromic acid, phosphonic acid, sulfuric acid, tartaric acid, acetic acid, citric acid, malic acid, methanesulphonic acid and gluconic acid.
Abstract:
A composition comprising 5-[4'-(piperidinomethyl)phenyl]-2,3-dihydroimidazo [2,1-a] isoquinoline is provided to inhibit inflammation and regulate immune responses in macrophages, thereby preventing and treating the inflammatory or immune diseases. The composition for prevention and treatment of inflammatory or immune diseases comprises 5-[4'-(piperidinomethyl)phenyl]-2,3-dihydroimidazo [2,1-a] isoquinoline or its pharmaceutically acceptable salt, and inhibits the expression of any one proinflammatory cytokine selected from the group consisting of IL-1(interleukin) beta, IL-6 and TNF-alpha(tumor necrosis factor-alpha).
Abstract:
An extract of Hibiscus cannabinus L., Malvaceae is provided to control the function of macrophage by inhibiting generation of TNF-alpha, mRNA expression of interleukin(IL)-3 and IL-12, and generation of nitric oxide(NO), prostaglandin(PGE2) and reactive oxygen species(PROS), thereby being useful for preventing and treating diseases by immuno-reaction. A pharmaceutical composition for preventing and treating inflammation comprises an extract of Hibiscus cannabinus L. Malvaceae as an effective ingredient, wherein the extract is prepared by extracting the Hibiscus cannabinus L. with at least one solvent selected from the group consisting of water, C1-4 alcohol, glycerol, propylene glycol, 1,3-butyleneglycol, ethylacetate, benzene, hexane, diethyl ether and dichloromethane, filtering the extract and concentrating the filtrate.